102
Views
11
CrossRef citations to date
0
Altmetric
REVIEW ARTICLE

Antiretroviral treatment of HIV infection: Swedish recommendations 2007

, , , , , , , , , & show all
Pages 486-507 | Received 27 Mar 2007, Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Hiroyuki Gatanaga, Haruhito Honda & Shinichi Oka. (2008) Pharmacogenetic Information Derived from Analysis of HLA Alleles. Pharmacogenomics 9:2, pages 207-214.
Read now
Lars Navér, Ann-Britt Bohlin, Jan Albert, Leo Flamholc, Magnus Gisslén, Katarina Gyllensten, Filip Josephson, Pehrolov Pehrson, Anders Sönnerborg, Katarina Westling & Susanne Lindgren. (2008) Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007. Scandinavian Journal of Infectious Diseases 40:6-7, pages 451-461.
Read now

Articles from other publishers (9)

Enrico Ripamonti, Arvid Edén, Staffan Nilsson, Anders Sönnerborg, Henrik Zetterberg & Magnus Gisslén. (2022) Longitudinal decline of plasma neurofilament light levels after antiretroviral initiation in people living with HIV. Journal of Internal Medicine 293:4, pages 445-456.
Crossref
Dinko Rekić, Oskar Clewe, Daniel Röshammar, Leo Flamholc, Anders Sönnerborg, Vidar Ormaasen, Magnus Gisslén, Angela Äbelö & Michael Ashton. (2011) Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy. The AAPS Journal 13:4, pages 598-605.
Crossref
Dinko Rekić, Daniel Röshammar, Jackson Mukonzo & Michael Ashton. (2011) In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype . British Journal of Clinical Pharmacology 71:4, pages 536-543.
Crossref
Ola Ghatnekar, Catharina Hjortsberg, Magnus Gisslén, Stefan Lindbäck & Mickael Löthgren. (2012) Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden. PharmacoEconomics 28:S1, pages 49-57.
Crossref
Arvid EdénLars-Magnus AnderssonÖrjan AnderssonLeo FlamholcFilip JosephsonStaffan NilssonVidar OrmaasenVeronica SvedhemChrister SällAnders SönnerborgPetra TunbäckMagnus Gisslén. (2010) Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naïve HIV-1–Infected Patients. AIDS Research and Human Retroviruses 26:5, pages 533-540.
Crossref
Nanna Mykén, Boel Sundbeck, Godfrey Mpumilwa & Rune Andersson. (2009) Developing Countries Need Better Antiretroviral Drugs. Journal of the International Association of Physicians in AIDS Care 8:1, pages 23-24.
Crossref
Tobias Bergroth, Halime Ekici, Magnus Gisslén, Sabine Kinloch‐de Loes, Li‐Ean Goh, Andrew Freedman, Fiona Lampe, Margaret A. Johnson & Anders Sönnerborg. (2008) Selection of drug‐resistant HIV‐1 during the early phase of viral decay is uncommon in treatment‐naïve patients initiated on a three‐ or four‐drug antiretroviral regimen including lamivudine. Journal of Medical Virology 81:1, pages 1-8.
Crossref
Erik De Clercq. (2007) The design of drugs for HIV and HCV. Nature Reviews Drug Discovery 6:12, pages 1001-1018.
Crossref
Naveed Shaik, Nagdeep Giri, Guoyu Pan & William F. Elmquist. (2007) P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution. Drug Metabolism and Disposition 35:11, pages 2076-2085.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.